诺西那生治疗成人脊髓性肌萎缩症的单中心观察
治疗组客观运动功能无显著改善,5例报告主观改善,但不良反应包括严重头痛、细菌性脑膜炎等,3例因缺乏改善、反复肺炎或蛋白尿停药。
要点
- 成人SMA患者接受诺西那生治疗,客观运动功能无显著变化。
- 约半数治疗患者报告主观功能改善,可能部分为安慰剂效应。
- 诺西那生不良反应可严重,包括细菌性脑膜炎和需血补片的头痛。
核心结论
- 诺西那生的副作用可能很严重,尽管半数治疗患者报告主观功能 modest 改善,但无显著客观变化,可能主要反映安慰剂效应。
主要发现
- 治疗组平均医学研究理事会(MRC)评分变化百分比在12个月为2.5%,24个月为3.9%。
- 大多数未治疗患者保持稳定,3例略有下降;5例治疗患者报告主观改善。
- 治疗副作用包括5例腰椎穿刺后头痛(其中2例需血补片)和1例细菌性脑膜炎需住院治疗。
- 3例在治疗12-24个月后因缺乏改善、反复肺炎或蛋白尿停止治疗。
临床怎么用
- 成人SMA患者使用诺西那生需权衡主观获益与严重不良反应风险,并密切监测感染及蛋白尿等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report our experience with adult patients with spinal muscular atrophy (SMA), some of whom were treated with nusinersen. METHODS: We reviewed charts of adult patients with SMA seen in our neuromuscular clinic between 2017 and 2019 and noted their demographics, clinical characteristics, treatment, and side effects. RESULTS: Twenty-two patients were included. Nine had type 2 and 13 type 3 SMA. Median age was 36 years (range 20-71). Most could not walk unassisted. Ten patients had significant respiratory impairment necessitating ventilation and 2 had tracheostomy. Seventeen had severe scoliosis. Ten patients were treated with nusinersen for 6-24 months (median 12 months), 3 of whom required bone laminectomy for intrathecal access. One developed bowel and bladder incontinence following the procedure. In the treated group, on average, % Medical Research Council change was 2.5% at 12 months and 3.9% at 24 months. Most untreated patients remained stable; 3 had slightly declined. Five treated patients reported subjective improvement. Treatment side effects included post lumbar puncture headache in 5 patients, 2 of whom needed blood patch, and 1 bacterial meningitis requiring inpatient treatment. Three patients stopped treatment after 12-24 months due to lack of improvement, recurrent pneumonia, or proteinuria. CONCLUSION: Side effects of nusinersen can be serious. Whereas half of treated patients reported modest improvement in function, there were no significant objective changes, which may point largely to a placebo effect. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for some adult patients with SMA, nusinersen improves subjective function and causes serious adverse effects.
引用
- Moshe-Lilie O, Visser A, Chahin N, et al. Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center. Neurology. 2020. PMID: 32665408. doi:10.1212/WNL.0000000000009914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。